Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · WANBURY

WANBURY LTD

HealthcarePharmaceuticals & Biotechnology₹608 cr market cap
₹181.66 ▲ +4.17% today As of 19 Nov 2026
52-week low ₹163.3452-week high ₹344.75

-49.4% from the 52-week high · +6.8% above the low

Wanbury Ltd. engages in the business of pharmaceutical and related activities, including research. The company is headquartered in Navi Mumbai, Maharashtra. The firm is engaged in the business of pharmaceutical and related activities, including research. The firm operates through two divisions: the Active Pharmaceutical Ingredients (API) Business and the Domestic Formulations Business. The Company, through the Active Pharmaceutical Ingredients (API) Business, provides Metformin and Sertraline. Metformin is used for the treatment for type 2 diabetes and Sertraline is an anti-depressant. The company has approximately 13 API products. The company manufactures Metformin with over 8500 tons per year. Its products include Metformin HCL, Metformin DC/SR, Sertraline, Diphenhydramine, Mefenamic Acid, Glucosamine, Methoxsalen and Paroxetine. The firm's subsidiaries include Wanbury Holdings B. V. (Netherland), Wanbury Global FZE (UAE), Ningxia Wanbury Fine Chemicals Co. Ltd. (China) and Cantabria Pharma S. L. (Spain).

The short version. Promoter holding was 42.98% in Sep 2026, up 3.22 points over 8 quarters.

1 · The price

How has the stock traded?

WANBURY LTD trades 49.4% below its 52-week high and 6.8% above its 52-week low.

Change over period: —

1M-6.3%
3M-35.3%
6M-35.6%
1Y-25.2%

2 · The business

Is it growing?

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
Revenue183163172133161131139145
Net profit913201813410
Net margin %5.08.311.80.95.00.824.17.1
EPS (₹)2.614.16.180.372.450.3210.273.14

Annual

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue600576500511393367374374
Net profit3156-1081-1364-32-32
Net margin %5.19.7-2.115.9-3.217.5-8.6-8.6
EPS (₹)9.3217.09-3.1824.94-5.0425.79-13.49-13.49

3 · The quality

How well does it turn capital into profit?

.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %—51.5200.331.7
Return on capital %—27.866.1-67.3
EBITDA margin %—13.217.04.7
Net margin %—5.19.7-2.1

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
P/E ratio12.3

4 · The owners

Who holds it, and are they adding?

Promoter holding42.98%

Up 3.22 pts over 8 quarters.

Foreign institutions0.71%

Down 0.13 pts over 8 quarters.

Domestic institutions0.02%

Up 0.02 pts over 8 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter39.7639.7639.6343.0943.0843.0143.0142.98+3.22
FII0.841.551.590.820.720.590.890.71-0.13
DII0000000.060.02+0.02
Public59.458.6858.7856.0856.2156.3956.0356.28-3.12

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.02% of NAV
  • Bandhan BSE Healthcare Index Fund0.02% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for WANBURY LTD are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about WANBURY LTD

What is the WANBURY LTD share price?

WANBURY LTD (WANBURY) last closed at ₹181.66, up 4.17% on the day. Its 52-week range is ₹163.34 to ₹344.75.

What is the market cap of WANBURY LTD?

WANBURY LTD has a market capitalisation of about ₹608 crore. Its price-to-earnings ratio is 12.3.

How are WANBURY LTD's latest results?

Promoter holding was 42.98% in Sep 2026, up 3.22 points over 8 quarters.

Who owns WANBURY LTD?

As of Sep 2026, shareholding was: Promoter 42.98%, FII 0.71%, DII 0.02%, Public 56.28%.

How many mutual funds hold WANBURY LTD?

2 mutual fund schemes held WANBURY LTD in October 2026. That compares with 2 the month before.

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.